Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors.
Luo Y, Xia Y, Liu D, Li X, Li H, Liu J, Zhou D, Dong Y, Li X, Qian Y, Xu C, Tao K, Li G, Pan W, Zhong Q, Liu X, Xu S, Wang Z, Liu R, Zhang W, Shan W, Fang T, Wang S, Peng Z, Jin P, Jin N, Shi S, Chen Y, Wang M, Jiao X, Luo M, Gong W, Wang Y, Yao Y, Zhao Y, Huang X, Ji X, He Z, Zhao G, Liu R, Wu M, Chen G, Hong L; COCPO Consortium; Ma D, Fang Y, Liang H, Gao Q.
Luo Y, et al. Among authors: tao k.
Cell. 2024 Sep 5;187(18):4905-4925.e24. doi: 10.1016/j.cell.2024.06.013. Epub 2024 Jul 5.
Cell. 2024.
PMID: 38971151
Free article.
Clinical Trial.